Alipogene tiparvovec
- Generic Name
- Alipogene tiparvovec
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 929881-05-0
- Unique Ingredient Identifier
- 20OK4AFR4Y
- Background
Alipogene tiparvovec is an adeno-associated viral vector of serotype 1-based gene therapy that delivers the Ser(447)X variant of the human lipoprotein lipase (LPL) gene. It is being investigated for the treatment of lipoprotein lipase (LPL) deficiency.
- Associated Conditions
- -
- Associated Therapies
- -
Alipogene Tiparvovec for the Treatment of LPLD Patients
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- UniQure Biopharma B.V.
- Registration Number
- NCT02904772
- Locations
- 🇺🇸
Perelman School of Medicine at The University of Pennsylvania Translational Medicine & Human Genetics, Philadelphia, Pennsylvania, United States
🇨🇦Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath